CRSP
Price
$43.89
Change
-$0.54 (-1.22%)
Updated
Jun 20, 12:08 PM (EDT)
Capitalization
3.84B
52 days until earnings call
EDIT
Price
$2.23
Change
-$0.13 (-5.53%)
Updated
Jun 20, 04:07 PM (EDT)
Capitalization
196.73M
40 days until earnings call
Interact to see
Advertisement

CRSP vs EDIT

Header iconCRSP vs EDIT Comparison
Open Charts CRSP vs EDITBanner chart's image
CRISPR Therapeutics AG
Price$43.89
Change-$0.54 (-1.22%)
Volume$6.89K
Capitalization3.84B
Editas Medicine
Price$2.23
Change-$0.13 (-5.53%)
Volume$100
Capitalization196.73M
CRSP vs EDIT Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. EDIT commentary
Jun 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and EDIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 20, 2025
Stock price -- (CRSP: $44.43 vs. EDIT: $2.14)
Brand notoriety: CRSP and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 260% vs. EDIT: 2%
Market capitalization -- CRSP: $3.84B vs. EDIT: $196.73M
CRSP [@Biotechnology] is valued at $3.84B. EDIT’s [@Biotechnology] market capitalization is $196.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $335.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while EDIT’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 4 bearish.
  • EDIT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than EDIT.

Price Growth

CRSP (@Biotechnology) experienced а +7.01% price change this week, while EDIT (@Biotechnology) price change was +5.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.31%. For the same industry, the average monthly price growth was +31.28%, and the average quarterly price growth was +16.84%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

EDIT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+11.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.84B) has a higher market cap than EDIT($197M). EDIT YTD gains are higher at: 68.504 vs. CRSP (12.881). EDIT has higher annual earnings (EBITDA): -244.52M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. EDIT (221M). EDIT has less debt than CRSP: EDIT (31.1M) vs CRSP (219M). EDIT (35.8M) and CRSP (35M) have equivalent revenues.
CRSPEDITCRSP / EDIT
Capitalization3.84B197M1,948%
EBITDA-455.24M-244.52M186%
Gain YTD12.88168.50419%
P/E RatioN/AN/A-
Revenue35M35.8M98%
Total Cash1.86B221M839%
Total Debt219M31.1M704%
FUNDAMENTALS RATINGS
CRSP vs EDIT: Fundamental Ratings
CRSP
EDIT
OUTLOOK RATING
1..100
4223
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
4836
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
3595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (40) in the Biotechnology industry is in the same range as CRSP (66). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as EDIT (99). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (36) in the Biotechnology industry is in the same range as CRSP (48). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as EDIT (100). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPEDIT
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 11 days ago
76%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 22 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SQQQ22.500.03
+0.13%
ProShares UltraPro Short QQQ
HEZU40.490.03
+0.08%
iShares Currency Hedged MSCI Eurozn ETF
IGI16.390.01
+0.06%
Western Asset Investment Grade Opportunity Trust Inc
VSDM75.40-0.05
-0.07%
Vanguard Short Duration Tax-Exm Bd ETF
BGT12.30-0.03
-0.24%
BlackRock Floating Rate Income Trust